The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ImmunityBio
biotech company
Nothing else this week.
- FDA
Related events
- FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
- FDA approval precedes CDC sign-off on vaccines, and the Secretary appointed members to the CDC advisory committee.
- Experimental therapies require approval from the FDA.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- FDA approval enables commercial opportunity involving CBRE Group.
Coverage
Newest first; wire copies grouped- Insider MonkeyImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform We recently published 10 Best Biotech Stocks to Buy Under $10. ImmunityBio, Inc. is among them. ImmunityBio, Inc. (NASDAQ: